Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of INCB050465 (PI3Kδ inhibitor) in Relapsed or Refractory Follicular Lymphoma
2017-001624-22Phase 2Unknown
- Sponsor
- Incyte
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of parsaclisib in follicular lymphoma (FL) (2 arms), sponsored by Incyte. Primary endpoint: Objective response rate (ORR). Status: unknown.
02
Drugs
parsaclisib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2017-001624-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001624-22.